Aurora Cannabis Inc (ACB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aurora Cannabis Inc stock (ACB) is currently trading at $3.32. Aurora Cannabis Inc PS ratio (Price-to-Sales) is 0.49. Analyst consensus price target for ACB is $6.36. WallStSmart rates ACB as Sell.
- ACB PE ratio analysis and historical PE chart
- ACB PS ratio (Price-to-Sales) history and trend
- ACB intrinsic value — DCF, Graham Number, EPV models
- ACB stock price prediction 2025 2026 2027 2028 2029 2030
- ACB fair value vs current price
- ACB insider transactions and insider buying
- Is ACB undervalued or overvalued?
- Aurora Cannabis Inc financial analysis — revenue, earnings, cash flow
- ACB Piotroski F-Score and Altman Z-Score
- ACB analyst price target and Smart Rating
Aurora Cannabis Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Aurora Cannabis Inc (ACB) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Aurora Cannabis Inc (ACB) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Aurora Cannabis Inc (ACB) Areas to Watch (7)
Company is destroying shareholder value
Earnings declining -94.70%, profits shrinking
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very low institutional interest at 12.93%
Micro-cap company with very limited liquidity and high volatility
Modest revenue growth at 6.80%
Aurora Cannabis Inc (ACB) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.49), Price/Book (0.47) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Growth concerns include Revenue Growth at 6.80%, EPS Growth at -94.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -15.50%, Operating Margin at 2.32%, Profit Margin at -22.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -15.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 6.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ACB's Price-to-Sales ratio of 0.49x trades at a deep discount to its historical average of 100.74x (18th percentile). The current valuation is 100% below its historical high of 1263.78x set in Sep 2014, and 395% above its historical low of 0.1x in Jan 2024. Over the past 12 months, the PS ratio has compressed from ~0.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Aurora Cannabis Inc (ACB) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Aurora Cannabis Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 373M with 7% growth year-over-year. The company is currently unprofitable, posting a -22.5% profit margin.
Key Findings
Generating 11M in free cash flow and 17M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.19 indicates a conservative balance sheet with 56M in cash.
The company is unprofitable with a -22.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Aurora Cannabis Inc.
Bottom Line
Aurora Cannabis Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aurora Cannabis Inc(ACB)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.